169 related articles for article (PubMed ID: 32064620)
1. The role of miR-34 in cancer drug resistance.
Naghizadeh S; Mohammadi A; Duijf PHG; Baradaran B; Safarzadeh E; Cho WC; Mansoori B
J Cell Physiol; 2020 Oct; 235(10):6424-6440. PubMed ID: 32064620
[TBL] [Abstract][Full Text] [Related]
2. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
3. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
6. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
7. The Role of MicroRNAs in Diagnosis, Prognosis, Metastasis and Resistant Cases in Breast Cancer.
Teoh SL; Das S
Curr Pharm Des; 2017; 23(12):1845-1859. PubMed ID: 28231756
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Bahrami A; Aledavood A; Anvari K; Hassanian SM; Maftouh M; Yaghobzade A; Salarzaee O; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):774-786. PubMed ID: 28109133
[TBL] [Abstract][Full Text] [Related]
9. The potential prognostic and therapeutic application of tissue and circulating microRNAs in cervical cancer.
Hasanzadeh M; Movahedi M; Rejali M; Maleki F; Moetamani-Ahmadi M; Seifi S; Hosseini Z; Khazaei M; Amerizadeh F; Ferns GA; Rezayi M; Avan A
J Cell Physiol; 2019 Feb; 234(2):1289-1294. PubMed ID: 30191988
[TBL] [Abstract][Full Text] [Related]
10. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
11. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
13. Role of micro-RNAs in drug resistance of multiple myeloma.
Abdi J; Jian H; Chang H
Oncotarget; 2016 Sep; 7(37):60723-60735. PubMed ID: 27494872
[TBL] [Abstract][Full Text] [Related]
14. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
[TBL] [Abstract][Full Text] [Related]
15. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
16. The role of miR-130a in cancer.
Zhang HD; Jiang LH; Sun DW; Li J; Ji ZL
Breast Cancer; 2017 Jul; 24(4):521-527. PubMed ID: 28477068
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.
Uhr K; Prager-van der Smissen WJC; Heine AAJ; Ozturk B; van Jaarsveld MTM; Boersma AWM; Jager A; Wiemer EAC; Smid M; Foekens JA; Martens JWM
PLoS One; 2019; 14(5):e0216400. PubMed ID: 31063487
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs and cancer resistance: A new molecular plot.
Fanini F; Fabbri M
Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
[TBL] [Abstract][Full Text] [Related]
19. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
Bayraktar R; Van Roosbroeck K
Cancer Metastasis Rev; 2018 Mar; 37(1):33-44. PubMed ID: 29282605
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
